Microsoft Azure Growth Forecast Beats Expectations Amid Rising AI Competition 
Anthropic’s $1.5B AI Venture with Wall Street Firms Targets Private Equity Market 
Spirit Airlines Shuts Down Flights, Issues Refunds After Financial Collapse 
Supreme Court Asked to Reinstate Mail-Order Access to Abortion Pill Mifepristone 
NAB First-Half Earnings Miss Forecasts Amid Rising Global Risks 
Standard Chartered Q1 Profit Hits Record on Wealth and Investment Banking Growth 
Apple Q2 2026 Earnings Surge as iPhone 17 Sales Drive Record Revenue 
Hugo Boss Beats Q1 Profit Expectations Despite Market Headwinds 
Regis Resources and Vault Minerals to Merge in $10.7B Gold Deal 
Samsung Appoints New TV Business Head Amid Rising Competition from Chinese Rivals 
Apple Explores Intel and Samsung Partnerships to Diversify Chip Supply Chain 
Pinterest Stock Surges After Strong Q1 2026 Earnings Beat Expectations 
Berkshire Hathaway Q1 Earnings Jump 18% as Greg Abel Signals Disciplined Growth Strategy 
Meta Raises 2026 Capex Outlook Amid AI Spending Surge, Shares Drop After Earnings 
Palantir Reports Record Growth, Raises 2026 Revenue Outlook Above Expectations 
U.S. Cybersecurity Pushes Faster Patch Deadlines Amid Rising AI-Driven Threats 
REDWOOD CITY, Calif., May 03, 2018 -- Codexis, Inc. (NASDAQ:CDXS), a leading protein engineering company, announces that it will report first quarter 2018 financial results after market close on Thursday, May 10, 2018. Codexis management will hold an investment community conference call at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) to discuss financial results and provide a company update.
| Live Call: | U.S. | 855 890 8665 | |
| International | 720 634 2938 | ||
| Passcode | 9585106 | ||
| Live Webcast: | Codexis IR Website | ||
| The webcast will be archived for 30 days. | |||
| Replay: | U.S. | 855 859 2056 | |
| International | 404 537 3406 | ||
| Passcode | 9585106 | ||
| The replay will be available for 48 hours | |||
About Codexis, Inc.
Codexis is a leading protein engineering company that applies its proprietary CodeEvolver® technology to develop proteins for a variety of applications, including as biocatalysts for the commercial manufacture of pharmaceuticals, fine chemicals and industrial enzymes, and enzymes as biotherapeutics and for use in molecular diagnostics. Codexis’ proven technology enables improvements in protein performance, meeting customer needs for rapid, cost-effective and sustainable manufacturing in multiple commercial-scale implementations of biocatalytic processes. For more information, see www.codexis.com.
CONTACTS
Investors
LHA Investor Relations
Jody Cain, 310 691 7100
[email protected]
